P

Prostatype Genomics AB
STO:PROGEN

Watchlist Manager
Prostatype Genomics AB
STO:PROGEN
Watchlist
Price: 9.7 SEK -1.02% Market Closed
Market Cap: 49.9m SEK
Have any thoughts about
Prostatype Genomics AB?
Write Note

Relative Value

The Relative Value of one PROGEN stock under the Base Case scenario is 6.83 SEK. Compared to the current market price of 9.7 SEK, Prostatype Genomics AB is Overvalued by 30%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PROGEN Relative Value
Base Case
6.83 SEK
Overvaluation 30%
Relative Value
Price
P
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
64
vs Industry
34
Median 3Y
304.1
Median 5Y
88.1
Industry
8.1
Forward
3.8
vs History
vs Industry
Median 3Y
-22.9
Median 5Y
-39.8
Industry
23
Forward
-96
vs History
vs Industry
Median 3Y
-23.1
Median 5Y
-42
Industry
23.4
vs History
vs Industry
Median 3Y
-22.8
Median 5Y
-40.7
Industry
27.3
vs History
80
vs Industry
61
Median 3Y
26.7
Median 5Y
20.4
Industry
2.6
vs History
64
vs Industry
31
Median 3Y
301.9
Median 5Y
86.2
Industry
8.1
Forward
3.7
vs History
58
vs Industry
51
Median 3Y
39.5
Median 5Y
16.5
Industry
9.6
vs History
vs Industry
Median 3Y
-23.1
Median 5Y
-39.8
Industry
4.3
Forward
-1.5
vs History
vs Industry
Median 3Y
-23.1
Median 5Y
-39.8
Industry
3.8
Forward
-1.4
vs History
vs Industry
Median 3Y
-23.1
Median 5Y
-41.4
Industry
6
vs History
vs Industry
Median 3Y
-23
Median 5Y
-40.8
Industry
3.8
vs History
82
vs Industry
64
Median 3Y
37.9
Median 5Y
29.9
Industry
4.8

Multiples Across Competitors

PROGEN Competitors Multiples
Prostatype Genomics AB Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
Prostatype Genomics AB
STO:PROGEN
49.9m SEK 48.8 -1.2 -1.3 -1.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 380 957.8 -177 666.1 -215 743.3 -213 281.4
US
Abbvie Inc
NYSE:ABBV
302.3B USD 5.4 59.5 14.9 22.9
US
Amgen Inc
NASDAQ:AMGN
160.6B USD 4.9 38 17.7 33.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.3B USD 11.9 -263.2 26.7 28
US
Gilead Sciences Inc
NASDAQ:GILD
118.3B USD 4.2 939 10.4 10.4
US
Epizyme Inc
F:EPE
94.1B EUR 1 884.6 -480.9 -523.7 -509.7
AU
CSL Ltd
ASX:CSL
138.5B AUD 6.1 34.3 21.1 26.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
90.4B USD 6.5 19.4 17.9 19.9
US
Seagen Inc
F:SGT
39.3B EUR 18.2 -55.7 -59.8 -54
NL
argenx SE
XBRU:ARGX
33.4B EUR 18.2 -127.9 -102.8 -74.9
P/E Multiple
Earnings Growth
SE
P
Prostatype Genomics AB
STO:PROGEN
Average P/E: 218
Negative Multiple: -1.2
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -177 666.1 N/A
US
Abbvie Inc
NYSE:ABBV
59.5
412%
US
Amgen Inc
NASDAQ:AMGN
38
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -263.2
42%
US
Gilead Sciences Inc
NASDAQ:GILD
939
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -480.9 N/A
AU
CSL Ltd
ASX:CSL
34.3
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.4
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -127.9 N/A
EV/EBITDA Multiple
EBITDA Growth
SE
P
Prostatype Genomics AB
STO:PROGEN
Average EV/EBITDA: 18.1
Negative Multiple: -1.3
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -215 743.3 N/A
US
Abbvie Inc
NYSE:ABBV
14.9
28%
US
Amgen Inc
NASDAQ:AMGN
17.7
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.7
38%
US
Gilead Sciences Inc
NASDAQ:GILD
10.4
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -523.7 N/A
AU
CSL Ltd
ASX:CSL
21.1
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.8 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -102.8 N/A
EV/EBIT Multiple
EBIT Growth
SE
P
Prostatype Genomics AB
STO:PROGEN
Average EV/EBIT: 23.5
Negative Multiple: -1.3
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -213 281.4 N/A
US
Abbvie Inc
NYSE:ABBV
22.9
88%
US
Amgen Inc
NASDAQ:AMGN
33.4
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28
44%
US
Gilead Sciences Inc
NASDAQ:GILD
10.4
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -509.7 N/A
AU
CSL Ltd
ASX:CSL
26.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.9
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -74.9 N/A

See Also

Discover More
Back to Top